EPISODE · Feb 12, 2024 · 20 MIN
Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
from Medical Digest & Congress Report · host Medical Congress News
We asked Professor David F. McDermott, investigator of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO GU 2024. Video: https://medicaldigest.org/scientific-contents/standalonecontent:overall-survival-results-keynote-564-adjuvant-pembrolizumab-versus-placebo-renal-cell-carcinoma
Embed this episode
Ready to play
Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
No transcript for this episode yet
Similar Episodes
No similar episodes found.